{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-064024","form_type":"8-K","ticker":"UTHR","cik":"0001082554","company_name":"UNITED THERAPEUTICS Corp","filed_at":"2022-05-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:59.667416+00:00","generated_at":"2026-06-25T07:30:25.518257+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"FDA approves United Therapeutics' Tyvaso DPI for PAH and PH-ILD; launch underway","bullets":["FDA approved Tyvaso DPI (treprostinil inhalation powder) for PAH (WHO Group 1) and PH-ILD (WHO Group 3).","First dry powder inhaler approved for PAH and PH-ILD; patient availability expected June 2022.","BREEZE study (51 PAH patients) demonstrated safety/tolerance and improved 6-minute walk distance.","TYVASO DPI and Tyvaso Inhalation Solution are only FDA-approved therapies for PH-ILD.","Commercial launch activities underway, offering convenient treprostinil delivery via hand-held inhaler."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-064024","json":"https://secwatch.observer/filing/0001104659-22-064024.json","markdown":"https://secwatch.observer/filing/0001104659-22-064024.md","text":"https://secwatch.observer/filing/0001104659-22-064024.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1082554/000110465922064024/0001104659-22-064024-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1082554/000110465922064024/tm2216671d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T07:30:25.518257+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}